FDA Grants Priority Review to Pembrolizumab for MSI-H Cancer

FDA Grants Priority Review to Pembrolizumab for MSI-H Cancer

2016 Gastrointestinal Cancers Symposium

2016 Gastrointestinal Cancers Symposium

 

The phase II study enrolled 3 patient cohorts. The first 2 cohorts were patients with CRC, while the third cohort included 21 patients with any solid gastrointestinal tumor that had mismatch repair deficiency. This cohort was subsequently expanded by 50 patients. - See more at: http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-pembrolizumab-for-msih-cancer?p=2#sthash.0KTRFN2L.dpuf

The phase II study enrolled 3 patient cohorts. The first 2 cohorts were patients with CRC, while the third cohort included 21 patients with any solid gastrointestinal tumor that had mismatch repair deficiency. This cohort was subsequently expanded by 50 patients.
- See more at: http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-pembrolizumab-for-msih-cancer?p=2#sthash.ONBkU6YH.2gtb7QV6.dpuf

The phase II study enrolled 3 patient cohorts. The first 2 cohorts were patients with CRC, while the third cohort included 21 patients with any solid gastrointestinal tumor that had mismatch repair deficiency. This cohort was subsequently expanded by 50 patients.
- See more at: http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-pembrolizumab-for-msih-cancer?p=2#sthash.ONBkU6YH.2gtb7QV6.dpuf